Daniel A. Weiser, MD
- Practice Specialty
- Pediatrics, Pediatrics - Hematology-Oncology (Cancer)
- Medical Education
- State University of NY at Stony Brook School of Medicine
- Columbia University Medical Center, New York Presbyterian Hospital
- The Children's Hospital of Philadelphia
- Main Location
- Academic Title
- Assistant Professor, Department of Pediatrics
Assistant Professor, Department of Genetics
- Administrative Title
- Medical Director, Intra-abdominal solid tumor program
- Clinical Focus
Dr. Weiser’s particular areas of expertise include:
- Neuroblastoma and adrenal tumors
- Wilms tumor and other kidney (renal) tumors
- Hepatoblastoma and other liver tumors
- Germ cell tumors (including testicular and ovarian tumors)
- Thyroid and other rare tumors
- Experimental therapeutics
- Cancer genetics and biomarkers
- Research Focus
Our laboratory is focused on childhood cancer research with a goal of elucidating the underlying biology of the most aggressive malignancies. In such patients with typically incurable cancer, we are striving to identify new approaches to and types of treatment. We have multiple ongoing projects:
- Identification of biologic drivers of ultra-high-risk neuroblastoma. Neuroblastoma is one of the most common and deadly childhood cancers. Despite intensive research, there are limited therapeutic strategies for patients with de novo chemotherapy resistance that leads to particularly poor outcomes. We have been studying neuroblastoma since 2009 and are identifying additional biologic drivers of highly lethal tumors. We compare tumor features from patients with early death from tumor progression compared to those with a maintained complete response. We assess unique histo-morphologic and proteomic features and computationally integrate these data with genomic and transcriptomic datasets to develop a combined predictor of primary refractory disease. Patients with this entity require non-standard and/or intensified treatment. Oncogenic drivers are being characterized in the lab which will facilitate strategies for novel pharmacologic intervention.
- Characterization of neuroblastoma development from neural crest cells. We are studying pathways and interactions that results in uncontrolled cell proliferation early in neuroblastoma development with an ultimate goal of identifying new targets and approaches for pharmacologic intervention.
- Evaluation of novel combinatorial targeted therapeutic approaches in neuroblastoma. With expected outcomes lagging behind those of more common childhood cancers, children with neuroblastoma require new approaches to treatment. Our lab works with multiple international clinical and research consortium groups to perform preclinical studies that substantiate human clinical trials.
- Detection of circulating tumor DNA in osteosarcoma. With no reliable non-invasive approach for disease monitoring during and after treatment, we are applying cutting edge next-generation sequencing approaches to identify solid tumors with a blood-based “liquid” biopsies. This will allow clinicians to assess tumor responsiveness to chemotherapy and predict likelihood of recurrence.
- Assessment of accelerated aging using miRNA-seq in survivors of childhood cancer. Chemotherapy has many untoward effects on healthy cells and leads to many signs of accelerated aging in children treated for cancer. Using a known microRNA “aging” signature discovered at Albert Einstein College of Medicine, we are studying what causes this phenotype in childhood cancer, with a goal of offering improved intervention to minimize long-term toxicity of treatment.
Detection of circulating tumor DNA in patients with osteosarcoma.
Advancing Clinicopathologic Diagnosis of High-risk Neuroblastoma Using Computerized Image Analysis and Proteomic Profiling.
Advancing clinicopathologic diagnosis of high-risk neuroblastoma using computerized image analysis and proteomic profiling.
Adrenocortical carcinoma with extension to the inferior vena cava and right atrium: 20-month-old girl with TP53 mutation.
Ovary preservation in the treatment of childhood Meigs syndrome.
Limited intra-tumor versus inter-tumor heterogeneity as assessed by proteomic profiling of high-risk neuroblastoma
Characterizing primary refractory neuroblastoma: prediction of outcome by microscopic image analysis
Adrenocortical Carcinoma with Extension to the Inferior Vena Cava and Right Atrium: Report in a 20-month-old girl with a TP53 mutation
ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma.
Imaging in childhood cancer: a Society for Pediatric Radiology and Children's Oncology Group Joint Task Force report.
Daniel A. Weiser, MD, is a Medical Director of the Intra-abdominal Solid Tumor Program in the Pediatrics Hematology/Oncology department at Children’s Hospital at Montefiore. He is also Assistant Professor in the Pediatrics and Genetics departments at the Albert Einstein College of Medicine. His clinical focuses are neuroblastoma and adrenal tumors, Wilms tumor and other kidney (renal) tumors, hepatoblastoma and other liver tumors, germ cell tumors (including testicular and ovarian tumors), Thyroid and other rare tumors, experimental therapeutics, and cancer genetics and biomarkers. Dr. Weiser is actively involved in teaching and mentorship of trainees and takes great pride in his active participation in patient care.
Dr. Weiser received his Bachelor of Science in Neurobiology in 1995 at Haverford College, PA. In 2004, he received his Doctor of Medicine at Stony Brook University School of Medicine, NY. He is currently earning his Master of Science in Translational Research at the University of Pennsylvania. He began a residency in Pediatrics at the New York-Presbyterian, Columbia University in 2007. Dr. Weiser then completed a three-year fellowship in Pediatric Hematology/Oncology at The Children’s Hospital of Philadelphia.
Dr. Weiser’s research goals are to understand the role of certain genes in the risk, development, and treatment of cancer. The approaches taken and agents studied hold promise in the treatment of all solid tumors. Dr. Weiser’s laboratory focuses on childhood cancer research with a goal of elucidating the underlying biology of the most aggressive malignancies. He has multiple ongoing projects, such as identification of biologic drivers of neuroblastoma at ultra-high risk for treatment failure, characterization of neuroblastoma development from neural crest cells, and evaluation of novel combinatorial targeted therapeutic approaches in neuroblastoma, among others. His research has been published in many reviewed journals.
Dr. Weiser participates in the efforts of a number of professional organizations including the Children’s Oncology Group (COG), American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), and the American Academy of Pediatrics (AAP). He has received many awards including the Brigid Leventhal Special Merit Award through ASCO, and he has been awarded a prestigious K12 from the NCI for the training of the next generation of physician-scientists in pediatric cancer.
He is board certified in Pediatric Hematology/Oncology and General Pediatrics.